Skip to main content
Equibles
INBX logo

INBX · Inhibrx Biosciences, Inc. · Metrics

Track INBX — free

Use INBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$87.75 -2.85 (-3.14%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$1.29B
Shares
14.72M
Volume · Nov 12 226.49K Avg daily vol (3M) 305.28K

INBX metrics

80 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$87.75
Market cap
$1.29B

Price action

23 metrics
Price change (1W)
+4.4%
Price change (30D)
+4.0%
Price change (3M)
-7.9%
Price change (6M)
-23.2%
Price change (YTD)
+14.7%
Price change (1Y)
+16.4%
Trailing year
Price change (5Y)
—
52-week high
$141.84
52-week low
$58.39
Change from 52-week high
-36.1%
Change from 52-week low
+55.1%
Annualized volatility
82.3%
Annualized volatility (3M)
87.2%
Implied volatility (30D)
102.2%
IV rank (1Y)
32.1
IV percentile (1Y)
39.7
Beta
2.2
RSI (14D)
51.7
Price vs SMA 50
-6.4%
Price vs SMA 200
-2.1%
Avg volume (3M)
304,239
Relative volume
0.5
Average dollar volume
$30.37M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
14.72M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-9.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
638.5×
reciprocal yield 0.2%
EV / revenue historical average (5Y)
638.5×
reciprocal yield 0.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-08

Profitability

9 metrics
Gross margin
—
Operating margin
-10,386.5%
Trailing 12 months
Net margin
-10,773.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$127.81M
Net income (TTM)
−$138.18M
Trailing 12 months
Diluted EPS (TTM)
$-8.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-8.21
EBITDA per diluted share (TTM)
$-8.07
Net income per diluted share (TTM)
$-8.88
Operating cash flow per diluted share (TTM)
$-8.47
Free cash flow per diluted share (TTM)
$-8.47
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$6.62
Stock compensation per diluted share (TTM)
$0.75
Book value per share
$0.55

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
-108.3%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-108.0%
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-89.6%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
−$125.61M
Free cash flow (TTM)
−$131.90M
Quick ratio
5.1
Interest coverage
-8.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$42.94M
Latest balance sheet
Cash & equivalents
$133.34M
Total assets
$154.22M
Total debt
$176.28M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$131.89M
Capital expenditures (TTM)
$10,000
R&D (TTM)
$103.00M
SG&A (TTM)
—
Stock compensation (TTM)
$11.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
162
13F filer change QoQ
+27
Institutional ownership
99.9%
Conviction holders (share of 13F filers)
2.5%
Crowding (high-turnover and private-fund holders)
43.0%
Private-fund adviser ownership
41.6%
Active holders' share change QoQ
+11.8%
Holder tenure
7.1
Price vs estimated holder cost
+85.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.0%

Short interest

3 metrics
Short interest
23.0%
Latest settlement · 10.0 days to cover
Days to cover
10.0d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
$6.07M
Insider-sentiment score
94 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 88 filings 84 filers Visit website Investor relations